To test the impact of altered BAZ1A/SMARCA5 on expression of VDR target genes, we examined the correlations between either BAZ1A or SMARCA5 and the 1α,25(OH)2D3-regulated genes from RC43N and RC43T in the AA TMPRSS2 fusion negative tumors from TCGA-PRAD cohort. This evidence concerns the gene SMARCA5 and prostate adenocarcinoma.